drugset
drugset / Trial / NCT05086627

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

NCT05086627 ↗

Phase 2 Completed 118 enrolled Hebei Medical University Fourth Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a single-center, prospective, open-label, randomized controlled clinical study, and the purpose of this study was to compare the pathological complete response rate (PCR) of patients with locally advanced rectal cancer treated with short-course radiotherapy sequential Tislelizumab combined with CapeOX (group A) versus short-course radiotherapy sequential CapeOX (group B). A total of 100 patients with locally advanced rectal cancer will be enrolled in the study. These patients were randomly assigned to the experimental group (group A) and the control group (group B) in a ratio of 1:1.

Timeline

Start
2021-09-01
Primary completion
2024-07-30
Completion
2024-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous
Background Capecitabine Small molecule 1000 mg/m2 —
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications

No indication recorded.